ReviewAnnals of surgical oncology2026
The Landmark Series: Neoadjuvant Therapy for Patients with Resectable Gastroesophageal Junction Adenocarcinomas.
Review in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant therapy is a cornerstone of treatment for resectable gastroesophageal junction (GEJ) tumors. Despite substantial advancements, optimal regimen selection remains challenging owing to heterogeneity in clinical trial inclusion criteria and treatment algorithms. This review synthesizes findings from pivotal randomized trials to guide evidence-based selection of neoadjuvant treatment for GEJ adenocarcinoma. In 2006, the MAGIC trial established a survival benefit with perioperative chemotherapy with epirubicin, cisplatin, and fluorouracil (ECF) compared with surgery alone. Subsequently, in 2012, CROSS demonstrated improved overall survival (OS) and R0 resection rates with neoadjuvant chemoradiotherapy (CRT) using carboplatin and paclitaxel compared with surgery alone. CRT increased pathologic complete response (pCR) rates and decreased local recurrence rates, though it had limited impact on distant recurrence rates. In 2018, the FLOT4 trial demonstrated that perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) improved overall survival and pCR rates compared with ECF, making FLOT the new standard for perioperative chemotherapy. Several trials have since compared perioperative chemotherapy with neoadjuvant CRT. Neo-AEGIS found no survival difference; however, the predominance of ECF rather than FLOT in the chemotherapy arm limits its pertinence in the modern era. TOPGEAR demonstrated improved pCR with the addition of preoperative radiotherapy to FLOT, but no survival advantage. More recently, ESOPEC established FLOT's superiority over CROSS for OS, and MATTERHORN demonstrated improved event-free survival with the addition of immunotherapy to perioperative FLOT. FLOT is the current standard for neoadjuvant treatment in GEJ adenocarcinoma due to its superior survival outcomes. Integration of immunotherapy represents a promising avenue to further improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.